Strong end to VC year as Blend, Naurex and Allakos raise $86m
This article was originally published in Scrip
Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.
You may also be interested in...
Private Company Edition: Flagship ends 2017 with its biggest life science fund yet totaling $618m. Also, December sees a year-end surge in VC deals, including a $100m Series B round for Allakos.
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.